Medicenna Therapeutics Corp. (TSX: MDNA)

Medicenna Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	16.98	16.98	33.6	20.54	30.38	22.7
Trading Asset Securities	-	-	-	-	10.01	15
Cash & Short-Term Investments	16.98	16.98	33.6	20.54	40.39	37.7
Cash Growth	-49.45%	-49.45%	63.60%	-49.15%	7.12%	1490.10%
Other Receivables	1.16	1.16	0.86	1.31	0.41	0.06
Total Receivables	1.16	1.16	0.86	1.31	0.41	0.06
Prepaid Expenses	0.93	0.93	1.93	1.55	1.35	0.09
Total Current Assets	19.08	19.08	36.39	23.39	42.15	37.85
Net Property, Plant & Equipment	-	-	-	-	0.03	0.07
Other Intangible Assets	0.06	0.06	0.06	0.07	0.07	0.08
Total Assets	19.13	19.13	36.45	23.46	42.25	38
Accounts Payable	2.07	2.07	1.62	1.67	2.25	0.46
Accrued Expenses	0.79	0.79	2.18	0.95	1.83	1.32
Current Portion of Leases	-	-	-	-	0.03	0.04
Other Current Liabilities	11.08	11.08	3.16	-	-	-
Total Current Liabilities	13.94	13.94	6.96	2.62	4.11	1.82
Long-Term Leases	-	-	-	-	-	0.03
Total Liabilities	13.94	13.94	6.96	2.62	4.11	1.85
Common Stock	100.92	100.92	100.92	83.67	79.59	56.58
Additional Paid-In Capital	10.7	10.7	9.49	7.93	6.68	10.39
Retained Earnings	-106.45	-106.45	-80.98	-70.93	-48.36	-31.07
Comprensive Income & Other	0.02	0.02	0.06	0.17	0.23	0.25
Total Common Equity	5.19	5.19	29.49	20.84	38.15	36.15
Shareholders' Equity	5.19	5.19	29.49	20.84	38.15	36.15
Total Liabilities & Equity	19.13	19.13	36.45	23.46	42.25	38
Total Debt	-	-	-	-	0.03	0.07
Net Cash (Debt)	16.98	16.98	33.6	20.54	40.35	37.63
Net Cash Growth	-49.45%	-49.45%	63.60%	-49.11%	7.22%	1487.28%
Net Cash Per Share	0.24	0.24	0.52	0.38	0.81	1.18
Filing Date Shares Outstanding	76.18	76.18	69.64	56.3	53.55	48.5
Total Common Shares Outstanding	69.64	69.64	69.64	55.65	53.55	46.8
Working Capital	5.13	5.13	29.43	20.77	38.04	36.04
Book Value Per Share	0.07	0.07	0.42	0.37	0.71	0.77
Tangible Book Value	5.13	5.13	29.43	20.77	38.07	36.07
Tangible Book Value Per Share	0.07	0.07	0.42	0.37	0.71	0.77

Source: S&P Capital IQ. Standard template.